Skip to main content
. 2023 Apr 13;44(9):1920–1931. doi: 10.1038/s41401-023-01083-w

Fig. 7. Inhibition of USP10 synergizes with CDK4/6 inhibitor to induce MM cell apoptosis.

Fig. 7

a, b OPM2 and KMS11 cells were treated with Spautin-1 for 24 h, followed by cell lysate preparation and IP/IB assays as indicated. c, d OPM2 and KMS11 cells were treated with Spaulin-1 at increased concentrations for 24 h (c) or 10 µM for indicated periods (d), followed by IB assays. e Cells were treated with Spaulin-1 and/or Palbociclib (Palb) for 24 h, followed by flow cytometric analysis after Annexin V-FITC and PI staining. f–i Balb/c immunodefficient mice were injected subcutaneously with KMS11 or OPM2 cells. When tumors were palpable, mice were randomly divided into 4 groups in each model, followed by administration of vehicle, Spautin-1, Palbociclib or Spau + Palb for 30 days. Tumor size was measured every three days (g, KMS11; i, OPM2). Tumors were excised at the end of the study (f, KMS11; h, OPM2). ##P < 0.01 when controls were analyzed against the treatments. **P < 0.01, the Spau+Pal combined treatment against the Spautin-1 or Palbociclib treatment.